Revvity (RVTY) investor relations material

Executive summary

• Q2 2026 delivered strong results with pro forma organic growth of 3% and revenue above guidance, driven by Diagnostics and AI-related demand in Life Sciences.

• Adjusted EPS was $1.41, up 23% year-over-year and above guidance, benefiting from strong operations, tax timing, and $16M in tariff refunds.

• Raised full-year 2026 guidance for organic growth, adjusted operating margin, and adjusted EPS.

• Signed definitive agreement to divest China Immunodiagnostics business, representing about 6% of 2025 revenue, expected to close by end of 2027.

• Innovation highlights include the launch of Signals AI, Anthropic connector, Signals for Startups, and FDA clearance of a Testosterone Assay.

Financial highlights

• Q2 2026 pro forma revenue: $711M, up 4% year-over-year; organic growth 3%; M&A contributed 1%.

• Adjusted operating margin: 29.3% in Q2, up 280bps year-over-year and above 27% outlook.

• Adjusted EPS: $1.41, up 23% year-over-year, with upside from tariff refunds and lower tax rate.

• Free cash flow: $184M in Q2, $299M year-to-date, with 108% conversion of adjusted net income.

• Retired €500M note in July, strengthening the balance sheet.

Outlook and guidance

• Full-year 2026 pro forma revenue guidance: $2.83B–$2.86B, 4–5% organic growth.

• Adjusted operating margin guidance increased to 28.7%.

• Adjusted EPS guidance raised to $5.30–$5.40; adjusted tax rate ~18%.

• Q3 organic growth expected at 4–6%; revenue $685M–$700M; operating margin ~29%.

• Diagnostics expected to grow high-single digits; Life Sciences low-single digits for full year.